File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1242/bio.059396
- Scopus: eid_2-s2.0-85143088640
- WOS: WOS:000950624400004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The prospect of genetically engineering natural killer cells for cancer immunotherapy
Title | The prospect of genetically engineering natural killer cells for cancer immunotherapy |
---|---|
Authors | |
Keywords | Cancer CAR-NK Cytokines Genetic engineering Immunotherapy NK cell |
Issue Date | 29-Nov-2022 |
Publisher | The Company of Biologists |
Citation | Biology Open, 2022, v. 11, n. 12 How to Cite? |
Abstract | The use of natural killer (NK) cells in cancer immunotherapy demonstrates promising potential, yet its efficacy is often limited due to the loss of tumor-killing capacity and lack of specificity in vivo. Here, we review current approaches to confer enhanced tumor-killing capacity and specificity by genetic engineering. Increasing sensitivity to cytokines and protecting NK cells from the immune checkpoint endowed sustainability of NK cells in the tumor microenvironment. Transducing chimeric antigen receptor (CAR) in NK cells successfully targeted both hematologic and solid tumors in preclinical models. The use of human pluripotent stem cells as an expandable and genetically amenable platform offers a stable source of engineered NK cells for cancer immunotherapy. We highlight that CAR-NK cells from human pluripotent stem cells are a promising approach for cancer immunotherapy. |
Persistent Identifier | http://hdl.handle.net/10722/331445 |
ISSN | 2023 Impact Factor: 1.8 2023 SCImago Journal Rankings: 0.758 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Poon, Angie Yu Ching | - |
dc.contributor.author | Sugimura, Ryohichi | - |
dc.date.accessioned | 2023-09-21T06:55:48Z | - |
dc.date.available | 2023-09-21T06:55:48Z | - |
dc.date.issued | 2022-11-29 | - |
dc.identifier.citation | Biology Open, 2022, v. 11, n. 12 | - |
dc.identifier.issn | 2046-6390 | - |
dc.identifier.uri | http://hdl.handle.net/10722/331445 | - |
dc.description.abstract | <p>The use of natural killer (NK) cells in cancer immunotherapy demonstrates promising potential, yet its efficacy is often limited due to the loss of tumor-killing capacity and lack of specificity <em>in vivo</em>. Here, we review current approaches to confer enhanced tumor-killing capacity and specificity by genetic engineering. Increasing sensitivity to cytokines and protecting NK cells from the immune checkpoint endowed sustainability of NK cells in the tumor microenvironment. Transducing chimeric antigen receptor (CAR) in NK cells successfully targeted both hematologic and solid tumors in preclinical models. The use of human pluripotent stem cells as an expandable and genetically amenable platform offers a stable source of engineered NK cells for cancer immunotherapy. We highlight that CAR-NK cells from human pluripotent stem cells are a promising approach for cancer immunotherapy.</p> | - |
dc.language | eng | - |
dc.publisher | The Company of Biologists | - |
dc.relation.ispartof | Biology Open | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Cancer | - |
dc.subject | CAR-NK | - |
dc.subject | Cytokines | - |
dc.subject | Genetic engineering | - |
dc.subject | Immunotherapy | - |
dc.subject | NK cell | - |
dc.title | The prospect of genetically engineering natural killer cells for cancer immunotherapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1242/bio.059396 | - |
dc.identifier.scopus | eid_2-s2.0-85143088640 | - |
dc.identifier.volume | 11 | - |
dc.identifier.issue | 12 | - |
dc.identifier.eissn | 2046-6390 | - |
dc.identifier.isi | WOS:000950624400004 | - |
dc.identifier.issnl | 2046-6390 | - |